These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22867774)

  • 1. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
    Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
    Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of censored medical cost data.
    Başer O; Gardiner JC; Bradley CJ; Yüce H; Given C
    Health Econ; 2006 May; 15(5):513-25. PubMed ID: 16389670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating lifetime or episode-of-illness costs under censoring.
    Basu A; Manning WG
    Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
    Sail KR; Franzini L; Lairson DR; Du XL
    Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
    Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
    Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient time costs associated with cancer care.
    Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
    J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-part model for censored medical cost data.
    Tian L; Huang J
    Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
    Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
    Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring costs: administrative claims data, clinical trials, and beyond.
    Etzioni R; Riley GF; Ramsey SD; Brown M
    Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
    Pelletier EM; Shim B; Goodman S; Amonkar MM
    Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population.
    Hadley J; Polsky D; Mandelblatt JS; Mitchell JM; Weeks JC; Wang Q; Hwang YT;
    Health Econ; 2003 Mar; 12(3):171-86. PubMed ID: 12605463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression analysis of incomplete medical cost data.
    Lin DY
    Stat Med; 2003 Apr; 22(7):1181-200. PubMed ID: 12652561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.
    Stokes ME; Thompson D; Montoya EL; Weinstein MC; Winer EP; Earle CC
    Value Health; 2008; 11(2):213-20. PubMed ID: 18380633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
    Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
    Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy.
    Heck JE; Albert SM; Franco R; Gorin SS
    J Am Geriatr Soc; 2008 Sep; 56(9):1687-92. PubMed ID: 18691280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
    Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
    Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of care for elderly cancer patients in the United States.
    Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
    J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.